'Dpp 4' presentation slideshows

Glycemic Management in Type 2 Diabetes

Glycemic Management in Type 2 Diabetes. Efficacy and Safety of Antihyperglycemic Therapies Introduced Since 2004. DPP-4 Inhibitors. DPP-4 Inhibitors. FDA-Approved Agents Alogliptin Linagliptin Saxagliptin Sitagliptin. Key Features Oral administration

999 views • 80 slides

????????

????????. ??? 2009-04-24 (09:00-10:30) ??????? ????????? ????? (MD, PhD). MANAGEMENT OF TYPE 2 DIABETES. ORAL ANTIDIABETIC AGENTS (OAD) INSULIN. MANAGEMENT OF TYPE 2 DIABETES. ORAL ANTIDIABETIC AGENTS (OAD) INSULIN. ORAL ANTIDIABETIC AGENTS.

956 views • 67 slides

DIABETES MELLITUS

DIABETES MELLITUS. BY Dr. HUSSEIN SAAD, MRCP (UK) Assistant Professor Consultant Family Medicine College of Medicine King Saud University. Genetic predisposition. Insulin Resistance (Hyperinsulinemia). ? Cell Defect. IGT. Type 2 Diabetes.

646 views • 62 slides

Diabetes Update

Diabetes Update. Maximizing options to achieve optimal blood glucose control. Carla Cox, PhD, RD, CDE. Be able to identify 3 lifestyle recommendations that could change your patients life with diabetes

718 views • 57 slides

?????????? : ? ????? ??? ??????? DPP-4 ???? ????????? ??????? ????? 2

?????????? : ? ????? ??? ??????? DPP-4 ???? ????????? ??????? ????? 2. ?? ??????? ????????. ??????? ?????????? ???? ??? ???? ??????. ????????? ?????????? Sympathetic innervation (?-receptors) Parasympathetic (cholinergic) innervation. ??????? ( ?? ????? ?????? ). ?????????.

937 views • 55 slides

Optimizing Diabetes Treatment in a Sea of Options

Optimizing Diabetes Treatment in a Sea of Options. Lucia M. Novak MSN, ANP-BC, BC-ADM, CDTC Nurse Practitioner The Diabetes Institute, Walter Reed National Military Medical Center Adjunct Assistant Professor The Uniformed Services University of the Health Sciences

687 views • 50 slides

Developments in the Treatment of T2DM

Developments in the Treatment of T2DM. Dr John Clark. 3 million. 2 million. Type 1. Type 2. 1 million. 0. 2013. 2000. 1995. Diabetes Prevalence. Audit of West Suffolk Hospital In-Patients. One day (23/9/12) 440 in-patients, in total, in WSH that day 75 known to have Diabetes

545 views • 42 slides

Javier Escalada

516 views • 37 slides

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 3 of 5

178 views • 16 slides

New Diabetes Drugs DPP-4 Inhibitors Exenatide

New Diabetes Drugs DPP-4 Inhibitors Exenatide. Incretin effect. GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose Type 2 diabetics little incretin effect Reduced GLP-1 secretion GIP lost insulinotropic property GLP-1 broken down by DPP-4

319 views • 11 slides

Diabetes Drugs Market Global Survey, Share, In-depth Analysis, Sales Revenue Forecasts to 2026

The Global Diabetes Drugs Market is likely to grow in the coming years due to recent advances in molecular data that has contributed to genome sequencing. According to a report published by Fortune Business Insights, titled u201cDiabetes Drugs Market: Global Market Analysis, Insights, and Forecast, 2018 to 2026,u201d the market will be valued at US$ 78,261.7 Mn by the end of 2026. Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570 Fortune Business Insights states that the market was valued at US$ 48,753.1 Mn in 2018 and is likely to exhibit a CAGR of 6.1% in the forecast period. Regional Analysis: Having said that, North America is likely to expand with the highest CAGR, due to an increasing patient pool and favorable reimbursement policies in this region, in the forecast period.

62 views • 5 slides